GO:1903979 negative regulation of microglial cell activation: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903979 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of microglial cell activation.
• Microglial activation is a double-edged sword: acute activation supports repair, but chronic activation drives neuroinflammation and neurodegeneration [1, 3].
• Key negative regulators include TREM2, CX3CR1, PPARA, METTL3, and astrocyte-derived factors that suppress microglial reactivity [2, 4, 5, 6, 8].
• Dysregulation of this process is linked to Alzheimer's disease, ischemic stroke, anxiety, and other neuroinflammatory conditions [4, 5, 6, 7].
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal roles of candidate genes in this pathway [2, 4, 8].
• Targeting negative regulators of microglial activation offers therapeutic potential for neurodegenerative and neuropsychiatric disorders [3, 5, 6].
Description
Microglia are the resident immune cells of the central nervous system and play critical roles in brain development, homeostasis, and injury response. Under physiological conditions, microglia survey the parenchyma and remain in a ramified, resting state. Upon detection of danger signals, they undergo morphological and functional changes collectively termed microglial activation, which includes proliferation, migration, phagocytosis, and release of inflammatory mediators [1, 3]. While acute activation is protective, sustained or excessive activation contributes to neurotoxicity and neurological disease [1, 3]. Therefore, negative regulation of microglial cell activation (GO:1903979) is a crucial homeostatic mechanism that restrains microglial reactivity and prevents collateral damage [1, 2]. This process is mediated by a complex network of cell-intrinsic and cell-extrinsic signals, including neuronal feedback, astrocytic factors, and metabolic cues [1, 2, 3]. Understanding the molecular players and regulatory logic of GO:1903979 is essential for developing therapies that modulate neuroinflammation without compromising host defense [4, 5, 6].
negative regulation of microglial cell activation At A Glance
| GO ID | GO:1903979 |
|---|---|
| GO term | negative regulation of microglial cell activation |
| Ontology | biological_process |
| Synonym | down regulation of microglial cell activation, down-regulation of microglial cell activation, downregulation of microglial cell activation, inhibition of microglial cell activation |
| Major function | Suppresses the initiation and maintenance of microglial activation, thereby limiting neuroinflammation and preserving neuronal function [1, 2, 3]. |
| Key regulators | TREM2, CX3CR1, PPARA, METTL3, astrocyte-derived factors, neuronal activity [1, 2, 4, 5, 6, 8]. |
| Associated diseases | Alzheimer's disease, ischemic stroke, anxiety, neuroinflammatory disorders [4, 5, 6, 7]. |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, imaging, flow cytometry [2, 4, 8]. |
What Is GO:1903979?
GO:1903979, negative regulation of microglial cell activation, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of microglial cell activation. It encompasses molecular signals, cellular interactions, and feedback loops that suppress the transition of microglia from a resting, surveillant state to an activated, pro-inflammatory phenotype. This regulation can occur at the level of receptor signaling, transcriptional reprogramming, metabolic rewiring, or intercellular communication [1, 2, 3].
Why Is negative regulation of microglial cell activation Important in Cell Biology?
Negative regulation of microglial cell activation is essential for maintaining central nervous system homeostasis and preventing chronic neuroinflammation. Dysregulation of this process is a common feature of neurodegenerative diseases, psychiatric disorders, and acute brain injuries [1, 3, 4, 5, 6, 7]. Understanding the molecular mechanisms that restrain microglial activation can reveal therapeutic targets to mitigate neuroinflammation while preserving beneficial immune functions [2, 3, 5].
• Prevents excessive neuroinflammation that damages neurons and synapses [1, 3].
• Maintains microglial surveillance without triggering harmful inflammatory cascades.
• Dysregulation is linked to Alzheimer's disease pathogenesis [4, 5].
• Plays a role in ischemic stroke outcomes by modulating neurogenesis.
• Influences anxiety-like behaviors in metabolic disorders.
• Involves astrocyte-microglia crosstalk that shapes neuroprotective responses [2, 3].
• Metabolic regulators such as PPARA and METTL3 modulate this process [4, 8].
• Neuronal activity and cathepsin S can feedback to control microglial reactivity [1, 5].
• Targeting negative regulators may offer new therapeutic strategies for neurodegeneration [3, 5, 6].
• CRISPR-based models are critical for causal validation of candidate regulators [2, 4, 8].
What Happens During negative regulation of microglial cell activation?
Neuronal Feedback Suppression of Microglial Activation
In simple terms: Neurons can send 'calm down' signals to microglia to keep them from overreacting.
Neuronal activity triggers negative feedback that suppresses microglial activation. Badimon et al. showed that neuronal activity induces microglial process convergence and release of factors that inhibit microglial activation, thereby maintaining homeostasis. This feedback loop involves purinergic signaling and helps prevent excessive microglial reactivity during normal brain function.
Astrocyte-Mediated Inhibition of Microglial Reactivity
In simple terms: Astrocytes can release molecules that tell microglia to stay quiet.
Astrocytes play a key role in suppressing microglial activation. Cameron et al. identified a molecular switch in astrocytes that promotes neuroprotective reactivity and inhibits microglial pro-inflammatory responses. Additionally, Rothhammer et al. demonstrated that microbial metabolites activate aryl hydrocarbon receptor (AHR) in astrocytes, which then suppresses microglial activation via a TGF-alpha-dependent mechanism.
Metabolic and Epigenetic Control of Microglial Activation
In simple terms: Cellular metabolism and gene expression changes can put brakes on microglial activation.
PPARA-mediated autophagy reduces Alzheimer's disease-like pathology by inhibiting microglial activation. METTL3, an m6A methyltransferase, stabilizes BATF mRNA in microglia and drives neuroinflammation; its inhibition may promote negative regulation of microglial activation. These findings highlight metabolic and epigenetic checkpoints that restrain microglial reactivity [4, 8].
Receptor-Mediated Suppression: TREM2 and CX3CR1
In simple terms: Certain receptors on microglia act like brakes when they bind their ligands.
TREM2 signaling inhibits IFNAR1-mediated microglial activation, and its impairment exacerbates neuroinflammation. The CX3CL1-CX3CR1 axis, when activated by neuronal cathepsin S, can promote neuroinflammation; however, under homeostatic conditions, CX3CR1 signaling helps maintain microglia in a quiescent state. These receptor systems are critical for negative regulation of microglial activation [5, 6].
Microglia-Neural Stem Cell Crosstalk in Stroke
In simple terms: After stroke, microglia and neural stem cells talk to each other to control neurogenesis.
Nath et al. showed that interactions between subventricular zone microglia and neural stem cells impact the neurogenic response in a mouse model of cortical ischemic stroke. This crosstalk can suppress excessive microglial activation and support tissue repair, highlighting the importance of negative regulation in stroke recovery.
Key Genes Involved in GO:1903979 negative regulation of microglial cell activation
The following genes and proteins are key players in the negative regulation of microglial cell activation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TREM2 | Inhibits IFNAR1 signaling to suppress microglial activation | Target for modulating neuroinflammation in anxiety and metabolic disorders |
| CX3CR1 | Receptor for CX3CL1; maintains microglial quiescence | Implicated in aging and Alzheimer's disease neuroinflammation |
| PPARA | Activates autophagy to reduce microglial activation | Therapeutic target for Alzheimer's disease |
| METTL3 | m6A methyltransferase that stabilizes BATF mRNA; drives neuroinflammation | Epigenetic regulator of microglial activation; potential target for neuroinflammatory diseases |
| AHR | Aryl hydrocarbon receptor in astrocytes; suppresses microglial activation via TGF-alpha | Mediates microbial metabolite effects on neuroinflammation |
| TGF-alpha | Astrocyte-derived factor that inhibits microglial activation | Effector of AHR signaling in neuroinflammation |
| IFNAR1 | Type I interferon receptor; promotes microglial activation when TREM2 is impaired | Target for anxiety and neuroinflammatory conditions |
| BATF | Transcription factor stabilized by METTL3; promotes neuroinflammation | Downstream effector of m6A modification in microglia |
| CTSS | Cathepsin S; neuronal protease that increases neuroinflammation via CX3CL1-CX3CR1 | Linked to cognitive decline in aging and Alzheimer's disease |
| JAK2 | Kinase in JAK2-STAT3 pathway; mediates neuroinflammation | Potential target for blocking cathepsin S-induced microglial activation |
| STAT3 | Transcription factor downstream of JAK2; promotes neuroinflammation | Modulates microglial activation in aging and Alzheimer's disease |
| CX3CL1 | Neuronal chemokine ligand for CX3CR1; can promote or suppress activation | Bidirectional regulator of microglia-neuron communication |
| P2RY12 | Purinergic receptor involved in neuronal feedback suppression | Mediates neuronal activity-dependent microglial inhibition |
| AHR ligands | Microbial metabolites that activate AHR in astrocytes | Dietary or microbial modulation of neuroinflammation |
| TGF-beta | Anti-inflammatory cytokine that suppresses microglial activation | Astrocyte-derived factor in neuroprotective reactivity |
| IL-10 | Anti-inflammatory cytokine that inhibits microglial activation | Potential therapeutic for neuroinflammation |
| NGF | Neurotrophic factor that can modulate microglial reactivity | Astrocyte-derived neuroprotective factor |
How Is negative regulation of microglial cell activation Regulated?
Negative regulation of microglial cell activation is controlled by multiple layers of regulation, including neuronal feedback, astrocyte-derived factors [2, 3], metabolic sensors such as PPARA, and epigenetic modifiers like METTL3. The JAK2-STAT3 pathway downstream of CX3CL1-CX3CR1 signaling also modulates this process. TREM2 signaling acts as a brake on IFNAR1-mediated activation. These pathways converge to maintain microglia in a homeostatic state and prevent excessive neuroinflammation.
negative regulation of microglial cell activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPARA | Alzheimer's disease; autophagy and microglial suppression | APP/PS1 mice with PPARA overexpression or knockout |
| CTSS | Alzheimer's disease; cognitive decline via CX3CL1-CX3CR1 | Cathepsin S knockout or neuronal overexpression in AD mice |
| TREM2 | Anxiety; metabolic disorder; IFNAR1 signaling | TREM2 knockout mice under high-fat diet and intermittent hypoxia |
| METTL3 | Neuroinflammation; neurotoxicity | Microglia-specific METTL3 knockout or overexpression |
| AHR | Neuroinflammation; microbial metabolite signaling | AHR knockout mice or astrocyte-specific deletion |
Alzheimer's Disease
Impaired negative regulation of microglial activation contributes to Alzheimer's disease pathogenesis. PPARA activation reduces amyloid pathology and cognitive decline by enhancing autophagy and suppressing microglial activation. Neuronal cathepsin S promotes neuroinflammation via the CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway, leading to cognitive decline in aging and Alzheimer's disease. TREM2 dysfunction exacerbates neuroinflammation through IFNAR1 signaling.
Ischemic Stroke
After cortical ischemic stroke, microglia interact with neural stem cells in the subventricular zone to influence neurogenesis. Negative regulation of microglial activation is critical for creating a permissive environment for neural repair and limiting secondary damage.
Neuropsychiatric Disorders
Intermittent hypoxia exacerbates anxiety in high-fat diet-induced diabetic mice by inhibiting TREM2-regulated IFNAR1 signaling, leading to excessive microglial activation. This highlights the role of negative regulation in mood disorders associated with metabolic dysfunction.
Neuroinflammatory and Neurodegenerative Conditions
METTL3 drives neuroinflammation and neurotoxicity by stabilizing BATF mRNA in microglia, suggesting that dysregulation of m6A modification contributes to neuroinflammatory diseases. Astrocyte-mediated suppression of microglial activation via AHR and TGF-alpha is also important for limiting neuroinflammation.
From negative regulation of microglial cell activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X suppress microglial activation? | CRISPR knockout of gene X in microglial cell lines or primary microglia [2, 4, 8] |
| Does a point mutation in gene Y alter its inhibitory function? | CRISPR point mutation knock-in in iPSC-derived microglia or mouse models [2, 5] |
| Does overexpression of gene Z reduce neuroinflammation? | CRISPR knock-in of a strong promoter or lentiviral overexpression in microglia [4, 6] |
| How does tagged protein localize during microglial activation? | CRISPR knock-in of fluorescent or epitope tags [1, 8] |
| What is the transcriptional response to negative regulators? | RNA-seq after CRISPR activation or knockout [3, 7] |
| Can library screening identify novel suppressors? | Genome-wide CRISPR knockout or activation screen in microglial cells |
How to Study the negative regulation of microglial cell activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptomic changes | Identify genes regulated during microglial activation [4, 8] |
| Single-cell RNA-seq | Heterogeneity of microglial states | Characterize subpopulations in disease models |
| m6A-seq | m6A RNA methylation sites | Study METTL3-mediated regulation |
| Proteomics | Protein expression and modifications | Identify signaling changes in microglia [2, 5] |
| Two-photon imaging | Microglial morphology and motility | Real-time monitoring of activation in vivo |
| Flow cytometry | Surface marker expression | Quantify activated microglia in tissue [3, 6] |
| Cytokine ELISA | Pro-inflammatory mediator release | Assess suppression of microglial activation [4, 6] |
| Phagocytosis assay | Microglial phagocytic activity | Evaluate functional consequences of negative regulation [5, 7] |
Transcriptomic Profiling
RNA-seq and single-cell RNA-seq are used to identify gene expression changes during negative regulation of microglial activation. These methods reveal transcriptional programs driven by regulators such as PPARA, METTL3, and TREM2 [4, 6, 8].
Proteomic and Epigenetic Analysis
Proteomics and m6A-seq can uncover post-transcriptional and epigenetic mechanisms. METTL3-mediated m6A modification of BATF mRNA is an example of how epitranscriptomic regulation controls microglial activation.
Imaging and Flow Cytometry
Two-photon imaging and flow cytometry allow real-time visualization of microglial morphology and activation markers. Badimon et al. used in vivo imaging to show neuronal activity-dependent microglial process convergence.
Functional Assays
Phagocytosis assays, cytokine ELISAs, and neurotoxicity assays measure the functional consequences of negative regulation. These are used to test the impact of genes like CX3CR1, TREM2, and PPARA [4, 5, 6].
How CRISPR Can Be Used to Study GO:1903979 negative regulation of microglial cell activation
Knockout
CRISPR knockout of candidate negative regulators (e.g., PPARA, TREM2, METTL3) in microglial cells or mice allows assessment of their role in suppressing microglial activation. For example, METTL3 knockout reduces neuroinflammation by destabilizing BATF mRNA.
Point Mutation
CRISPR point mutation knock-in can model disease-associated variants in genes such as TREM2 or CX3CR1 to determine how specific mutations affect the negative regulation of microglial activation [5, 6].
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) or epitope tags into endogenous loci enables tracking of protein localization and dynamics during microglial activation [1, 2].
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of negative regulators like PPARA or AHR can enhance suppression of microglial activation and reduce neuroinflammation in disease models [3, 4].
How EDITGENE Supports negative regulation of microglial cell activation Research
Researchers studying negative regulation of microglial cell activation-related genes often need to determine whether a candidate gene is causally involved in suppressing microglial reactivity or is merely a correlative marker. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models and animal models for functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of microglial cell activation research.
Frequently Asked Questions About negative regulation of microglial cell activation
What is GO:1903979?
GO:1903979 is the Gene Ontology term for negative regulation of microglial cell activation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of microglial cell activation.
What genes are involved in negative regulation of microglial cell activation?
Key genes include TREM2, CX3CR1, PPARA, METTL3, AHR, and CTSS, among others [3, 4, 5, 6, 8].
How is microglial activation negatively regulated?
Through neuronal feedback, astrocyte-derived factors, metabolic sensors, epigenetic modifiers, and receptor-mediated signaling [1, 2, 3, 4, 8].
Why is negative regulation of microglial activation important?
It prevents chronic neuroinflammation and neuronal damage, and its dysregulation is linked to Alzheimer's disease, stroke, and anxiety [4, 5, 6, 7].
What diseases are associated with impaired negative regulation of microglial activation?
Alzheimer's disease, ischemic stroke, anxiety, and other neuroinflammatory conditions [4, 5, 6, 7].
How can I study negative regulation of microglial activation in the lab?
Use CRISPR knockout, knock-in, overexpression models, RNA-seq, imaging, and functional assays [2, 4, 8].
What is the role of TREM2 in microglial activation?
TREM2 inhibits IFNAR1 signaling to suppress microglial activation; its dysfunction exacerbates neuroinflammation.
How does METTL3 regulate microglial activation?
METTL3 stabilizes BATF mRNA via m6A modification, driving neuroinflammation; its inhibition may promote negative regulation.
Can CRISPR be used to study negative regulation of microglial activation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools for dissecting this process [2, 4, 8].
What models are available for studying negative regulation of microglial activation?
Microglial cell lines, primary microglia, iPSC-derived microglia, and mouse models of neurodegeneration [4, 5, 6, 7].
Conclusion
Negative regulation of microglial cell activation (GO:1903979) is a critical homeostatic process that restrains neuroinflammation and protects against neurological disease. Key regulators such as TREM2, CX3CR1, PPARA, and METTL3 have been identified through rigorous studies [4, 5, 6, 8]. Understanding the molecular mechanisms and causal relationships requires advanced CRISPR models and multi-omics approaches. EDITGENE provides comprehensive services to accelerate research in this field.
References
- 1. Badimon A et al.. 2020. Negative feedback control of neuronal activity by microglia.. Nature 586(7829):417-423 PMID: 32999463
- 2. Cameron EG et al.. 2024. A molecular switch for neuroprotective astrocyte reactivity.. Nature 626(7999):574-582 PMID: 38086421
- 3. Rothhammer V et al.. 2018. Microglial control of astrocytes in response to microbial metabolites.. Nature 557(7707):724-728 PMID: 29769726
- 4. Luo R et al.. 2020. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.. Autophagy 16(1):52-69 PMID: 30898012
- 5. Liu PP et al.. 2025. Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway in aging and Alzheimer's disease.. Aging Cell 24(2):e14393 PMID: 39453382
- 6. Ni W et al.. 2024. Intermittent hypoxia exacerbates anxiety in high-fat diet-induced diabetic mice by inhibiting TREM2-regulated IFNAR1 signaling.. J Neuroinflammation 21(1):166 PMID: 38956653
- 7. Nath S et al.. 2024. Interaction between subventricular zone microglia and neural stem cells impacts the neurogenic response in a mouse model of cortical ischemic stroke.. Nat Commun 15(1):9095 PMID: 39448558
- 8. Wu X et al.. 2025. The m(6)A methyltransferase METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia.. Cell Death Differ 32(1):100-117 PMID: 38902548
